1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	main	_	_	JJ	_	_	_	_	_
3	finding	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	our	_	_	PRP$	_	_	_	_	_
6	study	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	that	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	risk	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	AKI	_	_	NNP	_	_	_	_	_
13	rose	_	_	VBD	_	_	_	_	_
14	proportionally	_	_	RB	_	_	_	_	_
15	according	_	_	VBG	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	amount	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	pRBC	_	_	NN	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	FFP	_	_	CD	_	_	_	_	_
23	transfusions	_	_	NNS	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	both	_	_	CC	_	_	_	_	_
26	ABO-c	_	_	NNP	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	ABO-i	_	_	NNP	_	_	_	_	_
29	LT	_	_	NNP	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	but	_	_	CC	_	_	_	_	_
32	this	_	_	DT	_	_	_	_	_
33	association	_	_	NN	_	_	_	_	_
34	of	_	_	IN	_	_	_	_	_
35	pRBC	_	_	NNP	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	FFP	_	_	CD	_	_	_	_	_
38	transfusions	_	_	NNS	_	_	_	_	_
39	with	_	_	IN	_	_	_	_	_
40	post-transplant	_	_	JJ	_	_	_	_	_
41	AKI	_	_	NNP	_	_	_	_	_
42	was	_	_	VBD	_	_	_	_	_
43	stronger	_	_	JJR	_	_	_	_	_
44	in	_	_	IN	_	_	_	_	_
45	ABO-i	_	_	NNP	_	_	_	_	_
46	LT	_	_	NN	_	_	_	_	_
47	than	_	_	IN	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	ABO-c	_	_	NNP	_	_	_	_	_
50	LT	_	_	NNP	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Given	_	_	VBN	_	_	_	_	_
2	that	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	AKI	_	_	NNP	_	_	_	_	_
5	rates	_	_	NNS	_	_	_	_	_
6	increased	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	patients	_	_	NNS	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	preoperative	_	_	JJ	_	_	_	_	_
11	anemia	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	that	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	influence	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	transfusion	_	_	NN	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	AKI	_	_	NNP	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	more	_	_	RBR	_	_	_	_	_
22	pronounced	_	_	VBN	_	_	_	_	_
23	in	_	_	IN	_	_	_	_	_
24	ABO-i	_	_	NNP	_	_	_	_	_
25	LT	_	_	NN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	any	_	_	DT	_	_	_	_	_
29	efforts	_	_	NNS	_	_	_	_	_
30	to	_	_	TO	_	_	_	_	_
31	reduce	_	_	VB	_	_	_	_	_
32	perioperative	_	_	JJ	_	_	_	_	_
33	transfusions	_	_	NNS	_	_	_	_	_
34	may	_	_	MD	_	_	_	_	_
35	protect	_	_	VB	_	_	_	_	_
36	patients	_	_	NNS	_	_	_	_	_
37	with	_	_	IN	_	_	_	_	_
38	ABO-i	_	_	NNP	_	_	_	_	_
39	LT	_	_	NNP	_	_	_	_	_
40	against	_	_	IN	_	_	_	_	_
41	AKI	_	_	NNP	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	as	_	_	IN	_	_	_	_	_
4	our	_	_	PRP$	_	_	_	_	_
5	observations	_	_	NNS	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	from	_	_	IN	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	retrospective	_	_	JJ	_	_	_	_	_
10	analysis	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	prospective	_	_	JJ	_	_	_	_	_
13	trials	_	_	NNS	_	_	_	_	_
14	are	_	_	VBP	_	_	_	_	_
15	required	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	confirm	_	_	VB	_	_	_	_	_
18	our	_	_	PRP$	_	_	_	_	_
19	hypothesis	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Patient	_	_	NN	_	_	_	_	_
2	mortality	_	_	NN	_	_	_	_	_
3	and	_	_	CC	_	_	_	_	_
4	graft	_	_	NN	_	_	_	_	_
5	survival	_	_	NN	_	_	_	_	_
6	after	_	_	IN	_	_	_	_	_
7	ABO-i	_	_	NNP	_	_	_	_	_
8	LT	_	_	NNP	_	_	_	_	_
9	have	_	_	VBP	_	_	_	_	_
10	been	_	_	VBN	_	_	_	_	_
11	reported	_	_	VBN	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	be	_	_	VB	_	_	_	_	_
14	comparable	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	ABO-c	_	_	NNP	_	_	_	_	_
17	LT	_	_	NNP	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	although	_	_	IN	_	_	_	_	_
20	there	_	_	EX	_	_	_	_	_
21	is	_	_	VBZ	_	_	_	_	_
22	still	_	_	RB	_	_	_	_	_
23	concern	_	_	NN	_	_	_	_	_
24	regarding	_	_	VBG	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	high	_	_	JJ	_	_	_	_	_
27	incidence	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	antibody-mediated	_	_	JJ	_	_	_	_	_
30	rejection	_	_	NN	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	including	_	_	VBG	_	_	_	_	_
33	biliary	_	_	JJ	_	_	_	_	_
34	stricture	_	_	NN	_	_	_	_	_
35	related	_	_	VBN	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	a	_	_	DT	_	_	_	_	_
38	high	_	_	JJ	_	_	_	_	_
39	isoagglutinin	_	_	NN	_	_	_	_	_
40	titer	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	high	_	_	JJ	_	_	_	_	_
3	isoagglutinin	_	_	NN	_	_	_	_	_
4	titer	_	_	NN	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	provoke	_	_	VB	_	_	_	_	_
7	another	_	_	DT	_	_	_	_	_
8	major	_	_	JJ	_	_	_	_	_
9	organ	_	_	NN	_	_	_	_	_
10	injury	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	including	_	_	VBG	_	_	_	_	_
13	AKI	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	through	_	_	IN	_	_	_	_	_
16	an	_	_	DT	_	_	_	_	_
17	immunologic	_	_	JJ	_	_	_	_	_
18	response	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	AKI	_	_	NNP	_	_	_	_	_
3	affects	_	_	VBZ	_	_	_	_	_
4	graft	_	_	NN	_	_	_	_	_
5	outcomes	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	mortality	_	_	NN	_	_	_	_	_
8	after	_	_	IN	_	_	_	_	_
9	liver	_	_	NN	_	_	_	_	_
10	transplantation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	it	_	_	PRP	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	important	_	_	JJ	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	elucidate	_	_	VB	_	_	_	_	_
17	modifiable	_	_	JJ	_	_	_	_	_
18	risk	_	_	NN	_	_	_	_	_
19	factors	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	AKI	_	_	NNP	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	ABO-i	_	_	NNP	_	_	_	_	_
24	LT	_	_	NNP	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	reason	_	_	NN	_	_	_	_	_
3	why	_	_	WRB	_	_	_	_	_
4	AKI	_	_	NNP	_	_	_	_	_
5	occurs	_	_	VBZ	_	_	_	_	_
6	more	_	_	RBR	_	_	_	_	_
7	frequently	_	_	RB	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	ABO-i	_	_	NNP	_	_	_	_	_
10	LT	_	_	NNP	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	certain	_	_	JJ	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	although	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	high	_	_	JJ	_	_	_	_	_
18	isoagglutinin	_	_	NN	_	_	_	_	_
19	titer	_	_	NN	_	_	_	_	_
20	may	_	_	MD	_	_	_	_	_
21	play	_	_	VB	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	role	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	high	_	_	JJ	_	_	_	_	_
3	isoagglutinin	_	_	NN	_	_	_	_	_
4	titer	_	_	NN	_	_	_	_	_
5	may	_	_	MD	_	_	_	_	_
6	lead	_	_	VB	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	major	_	_	JJ	_	_	_	_	_
9	organ	_	_	NN	_	_	_	_	_
10	damage	_	_	NN	_	_	_	_	_
11	through	_	_	IN	_	_	_	_	_
12	possible	_	_	JJ	_	_	_	_	_
13	immunologic	_	_	JJ	_	_	_	_	_
14	injury	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	prevalent	_	_	JJ	_	_	_	_	_
6	baseline	_	_	NN	_	_	_	_	_
7	metabolic	_	_	JJ	_	_	_	_	_
8	alkalosis	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	low	_	_	JJ	_	_	_	_	_
11	platelet	_	_	NN	_	_	_	_	_
12	count	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	high	_	_	JJ	_	_	_	_	_
16	incidence	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	mild	_	_	JJ	_	_	_	_	_
19	arterial	_	_	JJ	_	_	_	_	_
20	hypoxemia	_	_	NN	_	_	_	_	_
21	prior	_	_	RB	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	transplantation	_	_	NN	_	_	_	_	_
24	surgery	_	_	NN	_	_	_	_	_
25	may	_	_	MD	_	_	_	_	_
26	contribute	_	_	VB	_	_	_	_	_
27	to	_	_	TO	_	_	_	_	_
28	the	_	_	DT	_	_	_	_	_
29	high	_	_	JJ	_	_	_	_	_
30	incidence	_	_	NN	_	_	_	_	_
31	of	_	_	IN	_	_	_	_	_
32	intraoperative	_	_	JJ	_	_	_	_	_
33	transfusion	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	low	_	_	JJ	_	_	_	_	_
36	oxygen	_	_	NN	_	_	_	_	_
37	delivery	_	_	NN	_	_	_	_	_
38	to	_	_	TO	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	kidney	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	ABO-i	_	_	NNP	_	_	_	_	_
6	LT	_	_	NNP	_	_	_	_	_
7	already	_	_	RB	_	_	_	_	_
8	receive	_	_	VBP	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	substantial	_	_	JJ	_	_	_	_	_
11	amount	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	FFP	_	_	NN	_	_	_	_	_
14	transfusion	_	_	NN	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	plasma	_	_	NN	_	_	_	_	_
17	exchange	_	_	NN	_	_	_	_	_
18	prior	_	_	RB	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	surgery	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	FFP	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	reported	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	risk	_	_	NN	_	_	_	_	_
9	factor	_	_	NN	_	_	_	_	_
10	for	_	_	IN	_	_	_	_	_
11	AKI	_	_	NNP	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	surgery	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	including	_	_	VBG	_	_	_	_	_
16	liver	_	_	NN	_	_	_	_	_
17	transplantation	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	risk	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	AKI	_	_	NNP	_	_	_	_	_
24	may	_	_	MD	_	_	_	_	_
25	increase	_	_	VB	_	_	_	_	_
26	when	_	_	WRB	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	ABO-i	_	_	NNP	_	_	_	_	_
30	LT	_	_	NNP	_	_	_	_	_
31	receive	_	_	VBP	_	_	_	_	_
32	intraoperative	_	_	JJ	_	_	_	_	_
33	FFP	_	_	NN	_	_	_	_	_
34	transfusions	_	_	NNS	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	an	_	_	DT	_	_	_	_	_
4	inflammatory	_	_	JJ	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	allergic	_	_	JJ	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	immunologic	_	_	JJ	_	_	_	_	_
10	reaction	_	_	NN	_	_	_	_	_
11	triggered	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	FFP	_	_	NN	_	_	_	_	_
14	transfusion	_	_	NN	_	_	_	_	_
15	may	_	_	MD	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	exacerbated	_	_	VBN	_	_	_	_	_
18	when	_	_	WRB	_	_	_	_	_
19	patients	_	_	NNS	_	_	_	_	_
20	receive	_	_	VBP	_	_	_	_	_
21	additional	_	_	JJ	_	_	_	_	_
22	intraoperative	_	_	JJ	_	_	_	_	_
23	FFP	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Red	_	_	JJ	_	_	_	_	_
2	cell	_	_	NN	_	_	_	_	_
3	transfusion	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	well-known	_	_	JJ	_	_	_	_	_
8	risk	_	_	NN	_	_	_	_	_
9	factor	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	AKI	_	_	NNP	_	_	_	_	_
12	after	_	_	IN	_	_	_	_	_
13	liver	_	_	NN	_	_	_	_	_
14	transplantation	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	negative	_	_	JJ	_	_	_	_	_
3	effect	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	pRBC	_	_	NN	_	_	_	_	_
6	transfusion	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	multifaceted	_	_	VBN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	includes	_	_	VBZ	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	systemic	_	_	JJ	_	_	_	_	_
13	inflammatory	_	_	JJ	_	_	_	_	_
14	response	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	contributes	_	_	VBZ	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	development	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	AKI	_	_	NNP	_	_	_	_	_
23	after	_	_	IN	_	_	_	_	_
24	surgery	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	large	_	_	JJ	_	_	_	_	_
3	amount	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	transfusion	_	_	NN	_	_	_	_	_
6	reflects	_	_	VBZ	_	_	_	_	_
7	excessive	_	_	JJ	_	_	_	_	_
8	surgical	_	_	JJ	_	_	_	_	_
9	bleeding	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	leads	_	_	VBZ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	renal	_	_	JJ	_	_	_	_	_
15	hypoperfusion	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	ischemia	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	resulting	_	_	VBG	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	poor	_	_	JJ	_	_	_	_	_
22	oxygen	_	_	NN	_	_	_	_	_
23	delivery	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	dose	_	_	NN	_	_	_	_	_
5	–	_	_	:	_	_	_	_	_
6	response	_	_	NN	_	_	_	_	_
7	relationship	_	_	NN	_	_	_	_	_
8	between	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	amount	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	pRBC	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	FFP	_	_	NN	_	_	_	_	_
15	transfusion	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	risk	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	AKI	_	_	NNP	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	our	_	_	PRP$	_	_	_	_	_
23	study	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	it	_	_	PRP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	clear	_	_	JJ	_	_	_	_	_
7	why	_	_	WRB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	undergoing	_	_	VBG	_	_	_	_	_
11	ABO-i	_	_	NNP	_	_	_	_	_
12	LT	_	_	NNP	_	_	_	_	_
13	were	_	_	VBD	_	_	_	_	_
14	more	_	_	RBR	_	_	_	_	_
15	susceptible	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	deleterious	_	_	JJ	_	_	_	_	_
19	effects	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	pRBC	_	_	NN	_	_	_	_	_
22	transfusion	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Possible	_	_	JJ	_	_	_	_	_
2	mechanisms	_	_	NNS	_	_	_	_	_
3	include	_	_	VBP	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	adverse	_	_	JJ	_	_	_	_	_
7	effect	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	pRBC	_	_	NN	_	_	_	_	_
10	transfusion	_	_	NN	_	_	_	_	_
11	may	_	_	MD	_	_	_	_	_
12	be	_	_	VB	_	_	_	_	_
13	aggravated	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	high	_	_	JJ	_	_	_	_	_
17	isoagglutinin	_	_	NN	_	_	_	_	_
18	titer	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	we	_	_	PRP	_	_	_	_	_
3	accounted	_	_	VBD	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	confounding	_	_	VBG	_	_	_	_	_
6	factors	_	_	NNS	_	_	_	_	_
7	through	_	_	IN	_	_	_	_	_
8	propensity-score-matching	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	multivariable	_	_	JJ	_	_	_	_	_
11	analysis	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	we	_	_	PRP	_	_	_	_	_
14	could	_	_	MD	_	_	_	_	_
15	not	_	_	RB	_	_	_	_	_
16	adjust	_	_	VB	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	isoagglutinin	_	_	NN	_	_	_	_	_
19	titer	_	_	NN	_	_	_	_	_
20	due	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	a	_	_	DT	_	_	_	_	_
23	lack	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	data	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	red	_	_	JJ	_	_	_	_	_
5	cell	_	_	NN	_	_	_	_	_
6	transfusion	_	_	NN	_	_	_	_	_
7	is	_	_	VBZ	_	_	_	_	_
8	closely	_	_	RB	_	_	_	_	_
9	related	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	FFP	_	_	CD	_	_	_	_	_
12	transfusion	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	Cumulative	_	_	JJ	_	_	_	_	_
2	FFP	_	_	NN	_	_	_	_	_
3	transfusion	_	_	NN	_	_	_	_	_
4	after	_	_	IN	_	_	_	_	_
5	preoperative	_	_	JJ	_	_	_	_	_
6	plasma	_	_	NN	_	_	_	_	_
7	exchange	_	_	NN	_	_	_	_	_
8	could	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	leading	_	_	VBG	_	_	_	_	_
12	cause	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	pRBC	_	_	NN	_	_	_	_	_
16	transfusion	_	_	NN	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	be	_	_	VB	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	simple	_	_	JJ	_	_	_	_	_
21	association	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	reduce	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	transfusion	_	_	NN	_	_	_	_	_
5	amount	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	ABO-i	_	_	NNP	_	_	_	_	_
8	LT	_	_	NNP	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	we	_	_	PRP	_	_	_	_	_
11	could	_	_	MD	_	_	_	_	_
12	adopt	_	_	VB	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	restrictive	_	_	JJ	_	_	_	_	_
15	transfusion	_	_	NN	_	_	_	_	_
16	policy	_	_	NN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	decreasing	_	_	VBG	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	transfusion	_	_	NN	_	_	_	_	_
21	threshold	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	there	_	_	EX	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	no	_	_	DT	_	_	_	_	_
5	established	_	_	VBN	_	_	_	_	_
6	consensus	_	_	NN	_	_	_	_	_
7	regarding	_	_	VBG	_	_	_	_	_
8	intraoperative	_	_	JJ	_	_	_	_	_
9	transfusion	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	pRBC	_	_	NNP	_	_	_	_	_
13	transfusion	_	_	NN	_	_	_	_	_
14	threshold	_	_	NN	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	our	_	_	PRP$	_	_	_	_	_
17	institution	_	_	NN	_	_	_	_	_
18	during	_	_	IN	_	_	_	_	_
19	liver	_	_	NN	_	_	_	_	_
20	transplantation	_	_	NN	_	_	_	_	_
21	was	_	_	VBD	_	_	_	_	_
22	around	_	_	RB	_	_	_	_	_
23	20	_	_	CD	_	_	_	_	_
24	%	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	hematocrit	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	threshold	_	_	NN	_	_	_	_	_
3	could	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	lowered	_	_	VBN	_	_	_	_	_
6	further	_	_	RBR	_	_	_	_	_
7	depending	_	_	VBG	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	baseline	_	_	NN	_	_	_	_	_
11	status	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	recipients	_	_	NNS	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	mixed	_	_	VBN	_	_	_	_	_
17	venous	_	_	JJ	_	_	_	_	_
18	oxygen	_	_	NN	_	_	_	_	_
19	concentrations	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Red	_	_	JJ	_	_	_	_	_
2	cell	_	_	NN	_	_	_	_	_
3	transfusion	_	_	NN	_	_	_	_	_
4	during	_	_	IN	_	_	_	_	_
5	surgery	_	_	NN	_	_	_	_	_
6	could	_	_	MD	_	_	_	_	_
7	possibly	_	_	RB	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	reduced	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	optimizing	_	_	VBG	_	_	_	_	_
12	baseline	_	_	NN	_	_	_	_	_
13	hematocrit	_	_	NN	_	_	_	_	_
14	before	_	_	IN	_	_	_	_	_
15	surgery	_	_	NN	_	_	_	_	_
16	through	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	administration	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	erythropoietin	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	previous	_	_	JJ	_	_	_	_	_
3	randomized	_	_	JJ	_	_	_	_	_
4	trial	_	_	NN	_	_	_	_	_
5	reported	_	_	VBD	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	preoperative	_	_	JJ	_	_	_	_	_
9	single	_	_	JJ	_	_	_	_	_
10	intravenous	_	_	JJ	_	_	_	_	_
11	dose	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	erythropoietin	_	_	NN	_	_	_	_	_
14	could	_	_	MD	_	_	_	_	_
15	reduce	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	transfusion	_	_	NN	_	_	_	_	_
18	amount	_	_	NN	_	_	_	_	_
19	during	_	_	IN	_	_	_	_	_
20	cardiac	_	_	JJ	_	_	_	_	_
21	surgery	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	thereby	_	_	RB	_	_	_	_	_
24	reducing	_	_	VBG	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	incidence	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	postoperative	_	_	JJ	_	_	_	_	_
29	AKI	_	_	NNP	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	reduce	_	_	VB	_	_	_	_	_
6	transfusion	_	_	NN	_	_	_	_	_
7	requirements	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	intraoperative	_	_	JJ	_	_	_	_	_
11	use	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	vasopressin	_	_	NN	_	_	_	_	_
14	was	_	_	VBD	_	_	_	_	_
15	reported	_	_	VBN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	reduce	_	_	VB	_	_	_	_	_
18	surgical	_	_	JJ	_	_	_	_	_
19	bleeding	_	_	NN	_	_	_	_	_
20	through	_	_	IN	_	_	_	_	_
21	selective	_	_	JJ	_	_	_	_	_
22	splanchnic	_	_	JJ	_	_	_	_	_
23	vasoconstriction	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	by	_	_	IN	_	_	_	_	_
26	reducing	_	_	VBG	_	_	_	_	_
27	portal	_	_	NN	_	_	_	_	_
28	blood	_	_	NN	_	_	_	_	_
29	flow	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	incidence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	AKI	_	_	NNP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	our	_	_	PRP$	_	_	_	_	_
7	study	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	within	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	range	_	_	NN	_	_	_	_	_
12	reported	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	previous	_	_	JJ	_	_	_	_	_
15	literature	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	incidence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	AKI	_	_	NNP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	ABO-i	_	_	NNP	_	_	_	_	_
7	LT	_	_	NNP	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	also	_	_	RB	_	_	_	_	_
10	similar	_	_	JJ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	a	_	_	DT	_	_	_	_	_
13	previous	_	_	JJ	_	_	_	_	_
14	study	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	risk	_	_	NN	_	_	_	_	_
3	factors	_	_	NNS	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	AKI	_	_	NNP	_	_	_	_	_
6	other	_	_	JJ	_	_	_	_	_
7	than	_	_	IN	_	_	_	_	_
8	ABO-i	_	_	NNP	_	_	_	_	_
9	LT	_	_	NNP	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	mostly	_	_	RB	_	_	_	_	_
12	consistent	_	_	JJ	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	those	_	_	DT	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	previous	_	_	JJ	_	_	_	_	_
18	literature	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	preoperative	_	_	JJ	_	_	_	_	_
3	hemoglobin	_	_	NN	_	_	_	_	_
4	level	_	_	NN	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	independently	_	_	RB	_	_	_	_	_
7	associated	_	_	VBN	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	post-transplant	_	_	JJ	_	_	_	_	_
10	AKI	_	_	NNP	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	MELD	_	_	NNP	_	_	_	_	_
3	score	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	consistently	_	_	RB	_	_	_	_	_
7	reported	_	_	VBN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	predictor	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	AKI	_	_	NNP	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Ischemic	_	_	JJ	_	_	_	_	_
2	time	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	not	_	_	RB	_	_	_	_	_
5	identified	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	independent	_	_	JJ	_	_	_	_	_
9	predictor	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	AKI	_	_	NNP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	our	_	_	PRP$	_	_	_	_	_
14	analysis	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	which	_	_	WDT	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	have	_	_	VB	_	_	_	_	_
19	been	_	_	VBN	_	_	_	_	_
20	due	_	_	JJ	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	relatively	_	_	RB	_	_	_	_	_
24	short	_	_	JJ	_	_	_	_	_
25	ischemic	_	_	JJ	_	_	_	_	_
26	time	_	_	NN	_	_	_	_	_
27	of	_	_	IN	_	_	_	_	_
28	LDLT	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

